Recently, great breakthroughs have been made in the
treatment of
melanoma with
immune checkpoint inhibitors. However, only a small proportion of
patients show a long-lasting response to
immunotherapy, and
risks of immune-related adverse events and
drug resistance have been also increasing along with the emergence of combination
treatment. This
review summarizes
biomarkers related to the
efficacy of
immune checkpoint inhibitors in the
treatment of
melanoma, aiming to predict and screen
out patients who may benefit from
immunotherapy, guide individualized clinical
treatment, and reduce the occurrence of
drug resistance and adverse reactions.